PMGC Authorizes 1.5B Shares and Formalizes AI Drug Expansion Program
ELAB is trading near its 52-week low of $4.97 (4.6% above the low) on light trading volume (0.3× avg).
Summary
PMGC Holdings increased authorized shares to 1.5 billion and formalized a three-phase AI drug expansion program with YuvaBio, advancing four compounds toward lead nomination in cardiac disease and obesity.
Key Events · Corporate Governance and Compliance · ELAB
-
Authorized Shares Increased to 1.5 Billion
Certificate of Amendment filed August 31, 2026 increases authorized capital stock to 1,500,000,000 shares — 1,000,000,000 common and 500,000,000 preferred — approved by holders of 60.34% of voting power.
-
Massive Dilution Headroom Created
The new authorization gives management the ability to issue up to 1 billion common shares, vastly exceeding the current outstanding count for a company with a $4.1M market cap and a going-concern warning from its Q2 10-Q.
-
AI Expansion Program Formalized
First Amendment to the YuvaBio license agreement launches a three-phase Expansion Program to advance all four AI-discovered compounds toward lead nomination, with fixed non-refundable fees (amount redacted) and a right of first refusal for the broader cardiometabolic field.
-
Field of Use Expanded
Amendment clarifies NorthStrive's exclusive field of use as Cardiac Diseases and Obesity, and grants a right of first refusal to negotiate an exclusive license across the broader cardiometabolic field for one year following Phase III completion.
Analysis · ELAB · Life Sciences
PMGC Holdings increased its authorized share count to 1.5 billion shares — a massive expansion of potential dilution headroom for a company with a $4.1M market cap and a going-concern warning. The filing also formalizes a three-phase Expansion Program with YuvaBio to advance four AI-discovered compounds toward lead nomination in cardiac disease and obesity, with fixed non-refundable fees and a right of first refusal across the broader cardiometabolic field. The share authorization is the more consequential item: it gives management the ability to issue up to 1 billion common shares, far exceeding the current outstanding count, which is a red flag for a company already relying on dilutive ELOC financing.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.5% of the 1996 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELAB was trading at $5.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $4.97 to $2,671.20. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.